Ideas to lND - Your Pathway to Discovery
Empowering Preclinical Innovation
Unlock the full potential of your preclinical research with Cyagen Biosciences. Our integrated solutions span from custom cell and animal model development through preclinical experiments, ensuring every phase of your project is expertly handled. Discover how we can help transform your innovative ideas into actionable outcomes and help translate your research discoveries into INDs.
OK to Switch
Receive Up to 15 Free NKG Mice for Trial
Explore
Innovative Solutions & Trusted Products
Special Promotions & Discounts
See All Promotions
Free Trial
OK to Switch - Introducing the Locally Bred NKG Mice
Cyagen is inviting researchers to experience the benefits of our NKG mice breed in the US. This "OK to Switch" offer is designed to help you easily transition from your current models with zero risk and gap.
Explore
Special Offer
Cell Line Project Special Offer
Get guaranteed, publication-ready cell lines without the endless troubleshooting. For a limited time, let our experts deliver your custom model for 50% less
Explore
Award
Cyagen Trailblazer Grant Award – Funding the Frontier of Model Generation
The Cyagen Trailblazer Grant Award (CTGA) 2025 is a global funding initiative supporting breakthroughs in biomedical research through the development of high-impact custom animal models. This year, Cyagen will provide up to $1 million USD in model generation funding to 50 research teams worldwide. Eligible research spans diverse areas, including cancer, neurological, cardiovascular, metabolic, immunological, and rare diseases. Researchers are invited to submit proposals and join an international community driving the future of preclinical research
Explore
Your Partners in Preclinical Progress
19
Years of Genetic Innovation
7,000
Global Bioscience Partners
50,000
Mouse & Rat Models Delivered
10,925
SCI Journal Citations
250,000
SPF Animals in AAALAC-Accredited Facilities
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Resource Library
BLOG & INSIGHTS
More Insights
Humanized ABCA4 Models Advance RNA & Gene Editing
Designed for translational research, Cyagen’s B6-hABCA4 and c.5461-10T>C mouse models enable preclinical testing of base editing, antisense oligonucleotides, and RNA editing therapies for Stargardt disease. These models offer precise genomic alignment with human ABCA4 mutations, enhancing clinical relevance.
October 16, 2025
Schedule Meeting
UPCOMING EVENT
More
Frontiers in Cancer Science 2025
Cyagen will be attending Frontiers in Cancer Science 2025 from November 5–7 in Singapore, where our experts will be on hand to discuss your drug development plans and introduce you to our advanced mouse models and comprehensive preclinical research services. We look forward to connecting with you!
Schedule Meeting
WEBINAR
More
Expanding the Cre-lox Toolbox: Advanced Targeting and a Comprehensive Repository of Conditional Mouse Models
This webinar will provide an understanding of Cyagen's innovative design pipeline, strategies for verifying Cre expression and specificity, and Taconic's best practices for breeding and maintaining Cre x floxed lines to ensure experimental reproducibility and translational relevance across research and development applications.
Schedule Meeting